Physician profile
Annjerald Devance
NPI 1629437785
$4,562.67
in general payments reported to CMS, 2019-2025
21 companies · $537 in 2025
The $537 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,042 · 2022: $441 · 2023: $1,448 · 2024: $1,096 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,080.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,727.14 | 2021-2025 | Fasenra, Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $523.62 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $304.23 | 2021-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $268.76 | 2021-2025 | |
| Abbvie INC. | $254.99 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $168.51 | 2021-2023 | Verquvo |
| Neurocrine Biosciences, INC. | $150.78 | 2024 | Ingrezza |
| Abbott Laboratories | $145.80 | 2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $128.56 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $124.34 | 2021 | |
| Gilead Sciences, INC. | $122.72 | 2024 | Epclusa |
| Urovant Sciences INC | $109.51 | 2021 | |
| Corcept Therapeutics | $99.04 | 2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $95.79 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.16 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $65.80 | 2021 | |
| Dexcom, INC. | $63.78 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $50.68 | 2021 | |
| Glaxosmithkline, LLC. | $37.92 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $23.38 | 2024 | |
| Supernus Pharmaceuticals, INC. | $21.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annjerald Devance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.